natgillin/translations-raw huggingface dataset:
In pregnant rabbits, no teratogenicity, embryotoxicity or fetotoxicity was observed at doses up to 240 mg/kg/day (approximately 23 times the MRHD on a mg/m2 basis.
Pri brejih kuncih niso opazili teratogenosti, embriotoksičnosti ali fetotoksičnosti pri odmerkih do 240 mg/kg/dan (približno 23-krat večjem odmerku od MRHD na podlagi mg/m2).
In pregnant rats, ibrutinib at a dose of 80 mg/kg/day was associated with increased post-implantation loss and increased visceral (heart and major vessels) malformations and skeletal variations with an exposure margin 14 times the AUC found in patients at a daily dose of 560 mg.
Pri brejih podganah je ibrutinib v odmerku 80 mg/kg/dan povečal število smrti zarodka po vgnezditvi in število visceralnih malformacij (na srcu in velikih žilah) ter skeletnih variacij pri meji izpostavljenosti, ki je bila 14-kratnik vrednosti AUC pri bolnikih, ki so prejemali dnevni odmerek 560 mg.
In pregnant rats, intravenous verteporfin doses of 10 mg/kg/day (approximately 40-fold human exposure at 6 mg/m2 based on AUCinf in female rats) were associated with an increased incidence of anophthalmia/microphthalmia and doses of 25 mg/kg/day (approximately 125-fold the human exposure at 6 mg/m2 based on AUCinf in female rats) were associated with an increased incidence of wavy ribs and anophthalmia/microphthalmia.
Pri brejih podganah so bili intravenski odmerki verteporfina 10 mg/kg/dan (kar pomeni približno 40- krat večjo izpostavljenost kot pri ljudeh po odmerjanju 6 mg/m2 glede na AUCinf pri podganjih samicah) povezani s povečano pogostnostjo anoftalmije/mikroftalmije, odmerki 25 mg/kg/dan (kar pomeni približno 125-krat večjo izpostavljenost kot pri ljudeh po odmerjanju 6 mg/m2 glede na AUCinf pri podganjih samicah) pa so bili povezani s povečano pogostnostjo valovite deformacije reber in anoftalmije/mikroftalmije.
In pregnant rats, no evidence of teratogenicity, embryotoxicity, or fetotoxicity was observed at doses up to 300 mg/kg/day (approximately 15 times the MRHD on a mg/m2 basis in a 60 kg subject).
Pri brejih podganah niso opazili nobenih znakov teratogenosti, embriotoksičnosti ali fetotoksičnosti pri odmerkih do 300 mg/kg/dan (približno 15-krat večjem odmerku od MRHD na podlagi mg/m2 pri osebi z maso 60 kg).
In pregnant rats, no maternal or fetal toxicity was observed at doses up to 575 micrograms/kg/day.
Pri brejih podganah pri odmerkih do 575 mikrogramov/kg/dan niso opazili toksičnosti za mater ali plod.
In pregnant rats, no maternal or fetal toxicity was observed at doses up to 575 µg/kg/day.
Pri brejih podganah niso opazili nobene toksičnosti za samice ali plod pri odmerkih do 575 µg/kg/dan.
In pregnant rats, no maternal or fetal toxicity was observed at doses up to 575 μg/kg/day.
Pri brejih podganah niso opazili nobene toksičnosti za samice ali plod pri odmerkih do
In pregnant women treated with lamivudine, more than 1000 outcomes from first trimester and more than 1000 outcomes from second and third trimester exposure indicate no malformative and foeto/neonatal effect.
Pri nosečnicah, ki so prejemale lamivudin, podatki iz več kot 1000 izidov po izpostavljenosti v prvem trimesečju in več kot 1000 izidov po izpostavljenosti v drugem in tretjem trimesečju, ne kažejo na malformacijske učinke lamivudina ali njegovih učinkov na plod ali novorojenčka.
In pregnant women, particularly near term pregnant women, prolonged dermal exposure increases the risk for premature closure of the ductus arteriosus in the foetus.
Dolgotrajnejše izpostavljanje kože zdravilu pri nosečnicah, zlasti blizu roka poroda, poveča tveganje za predčasno zaprtje duktusa arteriozusa pri plodu.
In premature infants there may be a slight rise in platelet counts, particularly up to day 12 - 14 of life, therefore platelets should be monitored regularly.
Pri nedonošenčkih lahko pride do rahlega porasta števila trombocitov, posebno do 12.–14. dneva po rojstvu, zato je število trombocitov treba redno nadzorovati.
In preparing the solution, the following two-step process must be carried out in an aseptic manner according to local standards for handling cytotoxic/cytostatic medicinal products:
Pri pripravi raztopine je treba na aseptičen način izvršiti naslednji dvostopenjski postopek v skladu z lokalnimi standardi za ravnanje s citotoksičnimi/citostatičnimi zdravili:
In preparing the solution, the following two-step process must be carried out in an aseptic manner according to local standards for handling cytotoxic/cytostatic medicines:
Pri pripravi raztopine morate na aseptičen način izvršiti naslednji dvostopenjski postopek v skladu z lokalnimi standardi za ravnanje s citotoksičnimi/citostatičnimi zdravili:
In presence of factors interfering with the immune system, in particular acute infections, the administration of Removab is not recommended.
V prisotnosti dejavnikov, ki vplivajo na imunski sistem, še zlasti akutnih okužb, se uporaba zdravila Removab ne priporoča.
In preterm infants born after at least 27 weeks of gestational age, the recommended immunisation series consists of four doses, each of 0.5ml.
Pri nedonošenčkih, rojenih z vsaj 27 tedni gestacijske starosti, obsega priporočeno imunizacijsko zaporedje štiri odmerke po 0,5 ml.
In preterm newborn infants less than 27 weeks of gestational age, the closure rate of the ductus arteriosus (33 to 50%) was shown to be low at the recommended dose regimen (see section 5.1).
Pri nedonošenčkih z gestacijsko starostjo pod 27 tednov je pogostnost zapiranja duktusa arteriozusa (33 do 50 %) ob priporočeni shemi odmerjanja manjša (glej poglavje 5.1.).
In preterm newborns ibuprofen significantly reduced plasma concentrations of prostaglandins and their metabolites, particularly PGE2 and 6-keto-PGF-1-alpha.
Ibuprofen pri nedonošenčkih pomembno zniža plazemsko koncentracijo prostaglandinov in njihovih presnovkov, predvsem PGE2 in 6-keto-PGF-1-alfa.
In previously untreated patients, Arzerra plus chlorambucil was effective at increasing progression-free survival, with patients living on average for 22.4 months without their disease getting worse, compared with 13.1 in patients given chlorambucil alone.
Pri bolnikih, ki predhodno niso bili zdravljeni, je bilo zdravilo Arzerra v kombinaciji s klorambucilom učinkovito in je podaljšalo čas preživetja bolnikov brez napredovanja bolezni in slabšanja stanja v povprečju za 22,4 meseca v primerjavi s 13,1 % pri bolnikih, ki so prejemali samo klorambucil.
In previously unvaccinated study participants who received one dose in year 1, efficacy was 57.7% (95% CI: 44.7, 67.9) and 56.3% (95% CI: 43.1, 66.7), respectively, thus supporting the need for two doses of vaccine in previously unvaccinated children. d In study participants who received 2 doses in year 1 and placebo in year 2, efficacy in year 2 was 56.2% (95% CI: 30.5, 72.7) and 44.8% (95% CI: 18.2, 62.9), respectively, in D153-P501, thus supporting the need for second-season revaccination. e The primary circulating strain was antigenically dissimilar from the H3N2 strain represented in the vaccine; efficacy against the mismatched A/H3N2 strain was 85.9% (95% CI: 75.3, 91.9).
Pri preiskovancih v študiji, ki se pred tem niso cepili in so prejeli le en odmerek v 1. letu, je bila učinkovitost 57,7% (95-% IZ: 44,7; 67,9) oziroma 56,3% (95-% IZ: 43,1; 66,7), to govori v prid potrebi po dveh odmerkih cepiva pri predhodno necepljenih otrocih. d Pri preiskovancih v študiji, ki so 1. leto prejeli 2 odmerka in placebo 2. leto, je bila učinkovitost 2. leto 56,2% (95-% IZ: 30,5; 72,7) oziroma 44,8% (95-% IZ: 18,2; 62,9) pri študiji D153-P501, kar govori v prid potrebi po revakcinaciji v drugi sezoni. e Primarni sev, ki je krožil, je bil antigensko različen od seva H3N2 v cepivu; učinkovitost proti neujemajočem se sevu A/H3N2 je bila 85,9% (95-% IZ: 75,3; 91,9).
In previously unvaccinated study participants who received one dose in year 1, efficacy was 57.7% (95% CI: 44.7, 67.9) and 56.3% (95% CI: 43.1, 66.7), respectively, thus supporting the need for two doses of vaccine in previously unvaccinated children. e In study participants who received 2 doses in year 1 and placebo in year 2, efficacy in year 2 was 56.2% (95% CI: 30.5, 72.7) and 44.8% (95% CI: 18.2, 62.9), respectively, in D153-P501, thus supporting the need for second-season revaccination. f The primary circulating strain was antigenically dissimilar from the H3N2 strain represented in the vaccine; efficacy against the mismatched A/H3N2 strain was 85.9% (95% CI: 75.3, 91.9).
Pri preiskovancih v študiji, ki se pred tem niso cepili in so prejeli le en odmerek v 1. letu, je bila učinkovitost 57,7 % (95-% IZ: 44,7; 67,9) oziroma 56,3 % (95-% IZ: 43,1; 66,7), to govori v prid potrebi po dveh odmerkih cepiva pri predhodno necepljenih otrocih. e Pri preiskovancih v študiji, ki so 1. leto prejeli 2 odmerka in placebo 2. leto, je bila učinkovitost 2. leto 56,2 % (95-% IZ: 30,5; 72,7) oziroma 44,8 % (95-% IZ: 18,2; 62,9) pri študiji D153-P501, kar govori v prid potrebi po revakcinaciji v drugi sezoni. f Primarni sev, ki je krožil, je bil antigensko različen od seva H3N2 v cepivu; učinkovitost proti neujemajočem se sevu A/H3N2 je bila 85,9 % (95-% IZ: 75,3; 91,9).
In primary and secondary hyperparathyroidism too much PTH is produced by the parathyroid glands.
Pri primarnem in sekundarnem hiperparatiroidizmu obščitnične žleze izločajo preveč PTH.
In primary hypercholesterolaemia and mixed dyslipidaemia, Repatha was studied in 9 main studies involving around 7,400 adult patients, including patients with heterozygous familial disease.
Zdravilo Repatha so pri zdravljenju primarne hiperholesterolemije in mešane dislipidemije proučevali v devetih glavnih študijah, v katere je bilo vključenih približno 7 400 odraslih bolnikov, vključno z bolniki s heterozigotno družinsko boleznijo.
In PROactive, a cardiovascular outcome study, 5238 patients with type 2 diabetes mellitus and pre- existing major macrovascular disease were randomised to pioglitazone or placebo in addition to existing antidiabetic and cardiovascular therapy, for up to 3.5 years.
V PROaktivni kardiovaskularni študiji izida je bilo 5238 bolnikov s sladkorno boleznijo tipa 2 in že prej obstoječimi težjimi makrovaskularnimi boleznimi naključno dodatno zdravljenih s pioglitazonom ali placebom k že obstoječemu antidiabetičnemu in kardiovaskularnemu zdravljenju, v trajanju do
In PROactive, a cardiovascular outcome study, 5238 patients with type 2 diabetes mellitus and pre- existing major macrovascular disease were randomised to pioglitazone or placebo in addition to existing antidiabetic and cardiovascular therapy, for up to 3.5 years.
V PROaktivni kardiovaskularni študiji izida je bilo 5238 bolnikov s sladkorno boleznijo tipa 2 in že prej obstoječimi težjimi makrovaskularnimi boleznimi naključno dodatno zdravljenih s pioglitazonom ali placebom k že obstoječemu antidiabetičnemu in kardiovaskularnemu zdravljenju, v trajanju do 3,5 let.
In PROactive, a cardiovascular outcome study, 5238 patients with type 2 diabetes mellitus and pre- existing major macrovascular disease were randomised to pioglitazone or placebo in addition to existing antidiabetic and cardiovascular therapy, for up to 3.5 years.
V PROaktivni študiji, ki ocenjuje kardiovaskularni izid, je bilo 5.238 bolnikov s sladkorno boleznijo tipa 2 in že prej obstoječimi težjimi makrovaskularnimi boleznimi naključno dodatno zdravljenih s pioglitazonom ali placebom k že obstoječemu antidiabetičnemu in kardiovaskularnemu zdravljenju, v trajanju do 3,5 let.
In prospective studies oral Prograf was investigated as primary immunosuppressant in approximately 175 patients following lung, 475 patients following pancreas and 630 patients following intestinal transplantation.
V prospektivnih študijah so zdravilo Prograf v peroralni obliki raziskovali kot primarni imunosupresiv pri približno 175 bolnikih po presaditvi pljuč, 475 bolnikih po presaditvi pankreasa in 630 bolnikih po presaditvi črevesa.
In prospective studies, Streptococcus pneumoniae was estimated to be responsible for 30-50% of pneumonia cases.
V prospektivnih študijah je bilo ocenjeno, da je za 30 - 50 % primerov bakterijskih pljučnic odgovoren Streptococcus pneumoniae.
In protease inhibitor (PI) experienced patients the choice of nelfinavir should be based on individual viral resistance testing and treatment history.
Izbira nelfinavirja pri bolnikih, že zdravljenih z zaviralci proteaz (PI – “protease inhibitor”), mora biti osnovana na testiranju virusne odpornosti posameznika in predhodnega zdravljenja.
In protease inhibitor (PI) experienced patients the choice of Telzir should be based on individual viral resistance testing and treatment history (see section 5.1).
Pri bolnikih, ki so predhodno že bili zdravljeni z zaviralcem proteaz (PI), mora izbira zdravila Telzir temeljiti na individualnem testiranju virusne rezistence in podatkih predhodnega zdravljenja bolnikov (glejte poglavje 5.1).
In Protocol 003, anti-HPV antibody GMTs at Month 7 among 16- through 26-year-old boys and men (HM) were comparable to anti-HPV antibody GMTs among 16- through 26-year-old girls and women for HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58.
V Protokolu 003 so bili GMT protiteles proti HPV v 7. mesecu pri dečkih in moških (heteroseksualni moški - HM), starih od 16 do 26 let, podobni kot GMT protiteles proti tipom HPV 6, 11, 16, 18, 31, 33, 45, 52 in 58 pri deklicah in ženskah, starih od 16 do 26 let.
In PROWESS, the incidence of serious bleeding events during the 28-day study period was 3.5% and 2.0% in drotrecogin alfa (activated)-treated and placebo-treated patients, respectively.
V študiji PROWESS je bila incidenca resnih krvavitev v 28-dnevnem trajanju študije 3,5 % oziroma 2,0 % pri bolnikih, zdravljenih z drotrekoginom alfa (aktiviranim), oziroma bolnikih, ki so prejemali placebo.
In PsA Study 1 and PsA Study 2, efficacy was maintained up to Week 52.
V 1. in 2. študiji psoriatičnega artritisa se je učinkovitost zdravila ohranjala do konca 52. tedna.
In PsA Study 2 there was a significant improvement in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scores in the ustekinumab groups when compared with placebo at week 24.
V 2. študiji PsA so v skupini, ki je 24 tednov prejemala ustekinumab, dokazali značilno izboljšanje funkcijske ocene zdravljenja kronične bolezni - utrujenosti (FACIT-F- Functional Assessment of Chronic Illness Therapy – Fatigue) v primerjavi s skupino, ki je prejemala placebo.
In PsA Study 2, among 200 patients initially randomised to Cosentyx 150 mg and 300 mg, 178 (89%) patients were still on treatment at Week 52.
V študiji psoriatičnega artritisa je med 200 bolniki, ki so bili že takoj randomizirani na zdravljenje z zdravilom Cosentyx 150 mg in 300 mg, 178 bolnikov (89%) ob koncu 52. tedna še vedno prejemalo zdravilo.
In PsA001 clinical trial, Cimzia-treated patients reported significant improvements in physical function as assessed by the Health Assessment Questionnaire – Disability Index (HAQ-DI), in pain as assessed by the PAAP and in tiredness (fatigue) as reported by the Fatigue Assessment Scale (FAS) as compared to placebo.
V kliničnem preskušanju PsA001 so v primerjavi s placebom bolniki, ki so se zdravili z zdravilom Cimzia, poročali o značilnih izboljšanjih telesnih funkcij, ocenjeno z indeksom nezmožnosti na osnovi vprašalnika za oceno zdravstvenega stanja (HAQ-DI - Health Assessment Questionnaire – Disability Index), značilnih izboljšanjih bolečine, ocenjeno sPAAP, in značilnih izboljšanjih glede utrujenosti, določeno z lestvico za ocenjevanje utrujenosti (FAS - Fatigue Assessment Scale).
In psoriasis and psoriatic arthritis clinical studies less than 8% of ustekinumab-treated patients developed antibodies to ustekinumab.
Protitelesa proti ustekinumabu so se v kliničnih študijah pojavila pri manj kot 8% zdravljenih bolnikih.
In psoriasis patients, treatment with infliximab resulted in decreases in epidermal inflammation and normalization of keratinocyte differentiation in psoriatic plaques.
Pri bolnikih s psoriazo je zdravljenje z infliksimabom povzročilo zmanjšanje vnetja v epidermisu in normalizacijo diferenciacije keratinocitov v psoriatičnih žariščih.
In psoriasis studies, the safety and efficacy of Cosentyx in combination with immunosuppressants, including biologics, or phototherapy have not been evaluated (see also section 4.5).
V študijah niso ocenjevali varnosti in učinkovitosti zdravila Cosentyx v kombinaciji z imunosupresivnim zdravljenjem, kar vključuje tudi biološka zdravila in fototerapijo (glejte tudi poglavje 4.5).
In psoriasis studies, the safety and efficacy of STELARA in combination with immunosuppressants, including biologics, or phototherapy have not been evaluated.
V študijah psoriaze varnosti in učinkovitosti zdravila STELARA v kombinaciji z drugimi imunosupresivi, vključno z biološkimi zdravili ali fototerapijo, še niso ovrednotili.
In psoriasis studies, the safety and efficacy of STELARA in combination with immunosuppressants, including biologics, or phototherapy have not been evaluated.
Varnost in učinkovitost zdravila STELARA v kombinaciji z imunosupresivi, vključno z biološkimi zdravili ali fototerapijo, v študijah psoriaze nista bili ovrednoteni.
In Psoriasis Study 2, the Hospital Anxiety and Depression Scale (HADS) and Work Limitations Questionnaire (WLQ) were also significantly improved in each ustekinumab treatment group compared with placebo.
V 2. študiji psoriaze sta bila tudi rezultata Bolnišnične lestvice tesnobe in depresije (Hospital Anxiety and Depression Scale - HADS) in vprašalnika o delovnih omejitvah (Work Limitations Questionnaire - WLQ) v obeh terapevtskih skupinah z ustekinumabom bistveno izboljšana v primerjavi s placebom.
In psoriasis, psoriatic arthritis and ankylosing spondylitis clinical studies, less than 1% of patients treated with Cosentyx developed antibodies to secukinumab up to 52 weeks of treatment.
V kliničnih študijah psoriaze, psoriatičnega artritisa in ankilozirajočega spondilitisa je pri manj kot 1 % bolnikov, ki so prejemali zdravilo Cosentyx, prišlo do razvoja protiteles proti sekukinumabu v obdobju do 52 tednov zdravljenja.
In psoriasis, psoriatic arthritis and ankylosing spondylitis clinical studies, less than 1% of patients treated with Cosentyx developed antibodies to secukinumab up to 52 weeks of treatment.
V kliničnih študijah psoriaze, psoriatičnega artritisa in ankilozirajočega spondilitisa je pri manj kot 1% bolnikov, ki so prejemali zdravilo Cosentyx, prišlo do razvoja protiteles proti sekukinumabu v obdobju do 52 tednov zdravljenja.
In Psoriatic Arthritis Study 1 (PsA Study 1) and Psoriatic Arthritis Study 2 (PsA Study 2) 29% and 35% of patients, respectively, were previously treated with an anti-TNFα agent and discontinued the anti-TNFα agent for either lack of efficacy or intolerance (anti-TNFα-IR patients).
V 1. študiji psoriatičnega artritisa je bilo 29%, v 2. študiji psoriatičnega artritisa pa 35% bolnikov predhodno zdravljenih z zaviralcem TNFα, zdravljenje z njim pa so prekinili bodisi zaradi neučinkovitosti ali neprenašanja zdravila (anti-TNFα neodzivni bolniki).
In psoriatic arthritis, Leflunomide Winthrop has been compared with placebo in 186 patients over six months.
Pri psoriatičenm artritisu so zdravilo Leflunomide Winthrop pri 186 bolnikih šest mesecev primerjali s placebom.
In psoriatic arthritis, Leflunomide Winthrop was more effective than placebo, with 59% of the patients taking Leflunomide Winthrop responding to treatment, compared with 30% of those taking placebo.
Pri psoriatičnem artritisu je bilo zdravilo Leflunomide Winthrop učinkovitejše od placeba, saj se je 59 % bolnikov, ki so jemali zdravilo Leflunomide Winthrop, odzvalo na zdravljenje, v primerjavi s 30 % tistih, ki so jemali placebo.
In psoriatic arthritis: leflunomide therapy is started with a loading dose of 100 mg once daily for 3 days.
Pri psoriatičnem artritisu: zdravljenje z leflunomidom se ponavadi začne z začetnim odmerkom 100 mg enkrat na dan 3 dni.
In psoriatic arthritis: leflunomide therapy is started with a loading dose of 100 mg once daily for 3 days.
Pri psoriatičnem artritisu: zdravljenje z leflunomidom se začne z začetnim odmerkom 100 mg enkrat na dan 3 dni.
In published literature reports, cases of non-mandibular osteonecrosis have been observed in patients under the age of 18 years treated with Avastin (please see section 5.3).
V literaturi so bili objavljeni primeri osteonekroze izven spodnje čeljustnice pri bolnikih, ki so se zdravili z zdravilom Avastin in so bili mlajši od 18 let (glejte poglavje 5.3).
In pulmonary arterial hypertension and heart failure, in the absence of endothelin receptor antagonism, elevated ET- 1 concentrations are strongly correlated with the severity and prognosis of these diseases.
Pri pljučni arterijski hipertenziji in srčnem popuščanju, če ni antagonizma na endotelinskih receptorjih, so povišane koncentracije ET-1 močno povezane z resnostjo in prognozo teh bolezni.
In pulmonary arterial hypertension and heart failure, in the absence of endothelin receptor antagonism, elevated ET-1 concentrations are strongly correlated with the severity and prognosis of these diseases.
Pri pljučni arterijski hipertenziji in srčnem popuščanju, če ni antagonizma na endotelinskih receptorjih, so povišane koncentracije ET-1 močno povezane z resnostjo in prognozo teh bolezni.
In pulmonary arterial hypertension patients, the oral bioavailability of sildenafil after 80 mg three times a day was on average 43 % (90 % CI: 27 % - 60 %) higher compared to the lower doses.
Pri bolnikih s pljučno arterijsko hipertenzijo je bila peroralna biološka uporabnost sildenafila ob 80 mg trikrat na dan v povprečju za 43 % (90 % IZ: od 27 do 60 %) večja kot ob manjših odmerkih.
In PV, treatment should also be interrupted when haemoglobin is below 8 g/dl.
Pri pravi policitemiji je treba zdravljenje prekiniti tudi v primeru, da je vrednost hemoglobina pod 8 g/dl.
In Quebec, Canada, Synflorix was introduced into the infant immunisation programme (2 primary doses to infants less than 6 months of age and a booster dose at 12 months) following 4.5 years of use of 7-valent Prevenar.
V Quebecu (Kanada) so cepivo Synflorix vpeljali v program cepljenja dojenčkov (2 primarna odmerka za dojenčke, mlajše od 6 mesecev, in obnovitveni odmerek po 12 mesecih) po 4,5 letih uporabe 7- valentnega cepiva Prevenar.
In RA patients, ALT and AST levels should be monitored every 4 to 8 weeks for the first 6 months of treatment followed by every 12 weeks thereafter.
Pri bolnikih z revmatoidnim artritisom je treba vrednosti ALT in AST prvih 6 mesecev zdravljenja kontrolirati na 4 do 8 tednov, pozneje pa na 12 tednov.
In RA patients, assessment of lipid parameters should be performed 4 to 8 weeks following initiation of RoActemra therapy.
Pri bolnikih z revmatoidnim artritisom je treba meritev lipidov opraviti od 4 do 8 tednov po uvedbi zdravljenja z zdravilom RoActemra.
In RA studies I-IV, Humira-treated patients achieved statistically significant ACR 20 and 50 responses compared to placebo as early as one to two weeks after initiation of treatment.
V študijah revmatoidnega artritisa I - IV so z zdravilom Humira zdravljeni bolniki v primerjavi s prejemniki placeba dosegli statistično značilen odziv 20 in 50 po ACR že en do dva tedna po začetku zdravljenja.
In RA studies I-IV, Humira-treated patients achieved statistically significant ACR 20 and 50 responses compared to placebo as early as one to two weeks after initiation of treatment.
V študijah revmatoidnega artritisa I–IV so bolniki, zdravljeni z zdravilom Humira, v primerjavi s prejemniki placeba doživeli statistično značilen odziv 20 in 50 po ACR že en do dva tedna po začetku zdravljenja.
In RA studies I-IV, Humira-treated patients achieved statistically significant ACR 20 and 50 responses compared to placebo as early as one to two weeks after initiation of treatment.
V študijah revmatoidnega artritisa I–IV so z zdravilom Humira zdravljeni bolniki v primerjavi s prejemniki placeba dosegli statistično značilen odziv 20 in 50 po ACR že en do dva tedna po začetku zdravljenja.